BELGRADE, SERBIA, July 23 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).
The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.
In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.
The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.
The aforementioned report will be posted shortly on the HTDS corporate web site www.htdsmedical.com and on Pink Sheets under the tab "FILINGS" - Supplemental Information. http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
Dr.Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem said "We are proud to be part of the Hard to Treat Diseases and we are grateful for the funding our division has received. This is of great assistance for continuing of our experiments. We have already ordered some chemicals and antibodies with the funding received. This has afforded us an opportunity to straighten our equipment and to introduce a new methodological approaches and techniques (like PCR and RT-PCR) that would give added value to our research".
Mr. Terry Yuan CEO said, "There is great synergy between the two companies Slavica BioChem and Mellow Hope. Although Slavica currently has no revenues, their developmental and research contributions have the potential to transform into enormous and massive gains for HTDS and its shareholders. We expect to be releasing HTDS Q2 financials shortly, and some positive updates on the IP issue very shortly. (see press release July 9, 2009 /PRNewswire-FirstCall via COMTEX/ for further details)"
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved